



Selonterra and Axxam Enter into Drug Discovery Collaboration

San Mateo, California (USA) and Milan, Italy - June 16th, 2020 - Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading discovery research company, announce a collaboration for the identification of novel small molecule therapies for Alzheimer's disease (AD), based on Selonterra's proprietary APOE4 mechanism.

Through this collaboration, Selonterra will have access to Axxam's expertise in discovery biology, in particular functional assays, and to its highly diverse and novel small molecule compound collection with the aim of developing small molecules acting on unexploited and highly druggable AD targets identified by Selonterra.

"We are very impressed by Axxam's capabilities in successfully completing the high-throughput screen on our most advanced AD target yielding small molecule modulators" said Roman Urfer, Founder and Chief Executive Officer of Selonterra. "We are excited to enter into this drug discovery collaboration to rapidly progress our program towards therapies for patients with AD".

"We are very pleased to be part of the impressive journey undertaken by Selonterra and thus contributing to their mission to develop new AD therapies on unprecedented targets" commented Stefan Lohmer, Chief Executive Officer of Axxam. "Combining their unique approach with our drug discovery platform, we will be able to support them in giving new hope to the patients affected by this disorder".

About Selonterra, Inc.

Selonterra, Inc. is a San Francisco Bay Area, venture capital-funded, biotechnology company. Selonterra pursues transformative approaches to the development of therapies for neurodegenerative disorders, including Alzheimer's disease. Selonterra harnesses human genetics, molecular pathway analysis and gene regulatory networks to identify proprietary disease-causing mechanisms and molecular targets, and exploit these to discover effective therapeutics. Selonterra's founders and advisors are scientists and executives with decades of biotech and pharma experience. Selonterra built a global network of specialized collaborator companies and applies state-of-the art technologies. For more information, please visit www.selonterra.com.

About Axxam S.p.A.

Axxam S.p.A. is a privately owned iPRO (innovative Partner Research Organization) and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of discovery services for the entire life sciences industries including pharmaceuticals, crop protection, animal health, cosmetics and nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including assay development, compound management, HTS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need. For more information, please visit www.axxam.com.